Trials / Completed
CompletedNCT00287417
Early Ultrasound and Maternal Biochemical Markers to Evaluate the Risk of Down Syndrome During the First Trimester
Nuchal Translucency Study - PAPP-A
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20,000 (actual)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The aim of the study is to evaluate the risk of Down syndrome during the first trimester of the pregnancy. The risk assessment is evaluated using early ultrasound and maternal biochemical markers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | echography | |
| OTHER | blood sample |
Timeline
- Start date
- 2003-07-01
- Completion
- 2011-02-01
- First posted
- 2006-02-06
- Last updated
- 2011-05-16
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00287417. Inclusion in this directory is not an endorsement.